Addex Therapeutics Files 6-K, Incorporates Exhibits
Ticker: ADXN · Form: 6-K · Filed: Jun 6, 2024 · CIK: 1574232
Sentiment: neutral
Topics: sec-filing, 6-K, registration-statement
Related Tickers: ADXN
TL;DR
Addex Therapeutics (ADXN) filed a 6-K, incorporating exhibits into existing SEC filings. No major news, just housekeeping.
AI Summary
Addex Therapeutics Ltd. filed a Form 6-K on June 6, 2024, incorporating by reference Exhibits 99.1 and 99.2 into its existing registration statements on Form F-3 and Form S-8. This filing does not appear to contain new financial information but rather updates or supplements existing filings.
Why It Matters
This filing indicates Addex Therapeutics is updating its SEC filings, which could be related to ongoing corporate actions or regulatory compliance, though specific details are not provided in this summary.
Risk Assessment
Risk Level: low — The filing is a routine SEC submission (Form 6-K) that incorporates existing exhibits into registration statements, suggesting it's procedural rather than announcing significant new developments.
Key Numbers
- 001-39179 — SEC File Number (Identifies Addex Therapeutics' filing with the SEC.)
- 333-255089 — Form F-3 Registration No. (Registration statement into which exhibits are incorporated.)
- 333-255124 — Form S-8 Registration No. (Registration statement into which exhibits are incorporated.)
- 333-272515 — Form S-8 Registration No. (Registration statement into which exhibits are incorporated.)
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- 001-39179 (company) — SEC File Number
- 333-255089 (company) — Form F-3 Registration Number
- 333-255124 (company) — Form S-8 Registration Number
- 333-272515 (company) — Form S-8 Registration Number
FAQ
What is the purpose of incorporating Exhibits 99.1 and 99.2 into the registration statements?
The filing states that Exhibits 99.1 and 99.2 to this Report on Form 6-K shall be deemed to be incorporated by reference into the specified registration statements on Form F-3 and Form S-8.
Which registration statements are being updated by this filing?
The filing specifically mentions incorporation into registration statement on Form F-3 (Registration No. 333-255089) and registration statements on Form S-8 (Registration No. 333-255124 and No. 333-272515).
Does this Form 6-K announce new financial results for Addex Therapeutics?
This Form 6-K is primarily for the incorporation of exhibits into existing registration statements and does not appear to announce new financial results.
What is the filing date of this Form 6-K?
This Form 6-K was filed on June 6, 2024.
What is the principal executive office address for Addex Therapeutics?
The principal executive offices are located at Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Filing Stats: 456 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2024-06-06 06:00:32
Filing Documents
- tm2416528d1_6k.htm (6-K) — 17KB
- tm2416528d1_ex99-1.htm (EX-99.1) — 525KB
- tm2416528d1_ex99-2.htm (EX-99.2) — 132KB
- tm2416528d1_ex99-3.htm (EX-99.3) — 41KB
- tm2416528d1_ex99-3img001.jpg (GRAPHIC) — 83KB
- 0001104659-24-068801.txt ( ) — 830KB
RISK FACTORS
RISK FACTORS Our business faces significant risks. You should carefully consider all of the information set forth in this Report on Form 6-K and in our other filings with the United States Securities and Exchange Commission, or the SEC, including the risk factors related to our business set forth in our Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission on April 18, 2024 and updated in our prospectus (No.333-271611) amended on April 24, 2024. Our business, financial condition, results of operations and growth prospects could be materially adversely affected by any of these risks. This report also contains forward-looking as a result of certain factors including the risks described in our Annual Report and our other SEC filings. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Addex Therapeutics Ltd By: /s/ Tim Dyer Name: Tim Dyer Date: June 6, 2024 Title: Chief Executive Officer 3 EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 : Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.2 : Management's Discussion and Analysis of Financial Condition and Result of Operations Exhibit 99.3 : Press Release dated June 6, 2024 4